Biopharmaceutical company Theravance Biopharma has enrolled its first patient in a Phase 3 registrational study of telavancin's efficacy in fighting Staphylococcus aureus bacteremia, officially launching its clinical trial.
Researchers will examine the efficacy of telavancin in treating patients with confirmed methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus bacteremia when compared with other, standard therapies.
The study will involve roughly 250 adult patients at 70 clinical sites in the U.S. and around the world.
Telavancin — marketed as VIBATIV — is a bactericidal, once-daily, injectable antibiotic that is approved in the U.S. for treating adult patients with hospital-acquired and ventilator-associated bacterial pneumonia. The antibiotic is also used for patients with complicated skin and skin structure infections caused by both MSSA and MRSA.
More articles on MRSA:
4 risk factors for MRSA infections in Mississippi
New silver solution proves effective in killing MRSA
FDA provides clearance for Roche MRSA/SA test